Prime Medicine, Inc. (PRME)
NASDAQ: PRME · IEX Real-Time Price · USD
4.300
-0.400 (-8.51%)
At close: Apr 25, 2024, 4:00 PM
4.420
+0.120 (2.79%)
Pre-market: Apr 26, 2024, 8:03 AM EDT
Prime Medicine Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Prime Medicine stock have an average target of 17.88, with a low estimate of 10 and a high estimate of 26. The average target predicts an increase of 315.81% from the current stock price of 4.30.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Prime Medicine stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 7 | 7 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $12 | Buy | Reiterates | $12 | +179.07% | Apr 23, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +295.35% | Apr 22, 2024 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Apr 8, 2024 |
| Wedbush | Wedbush | Buy Initiates $12 | Buy | Initiates | $12 | +179.07% | Apr 3, 2024 |
| Wedbush | Wedbush | Buy Initiates $12 | Buy | Initiates | $12 | +179.07% | Apr 2, 2024 |
Financial Forecast
Revenue This Year
13.11M
Revenue Next Year
8.93M
from 13.11M
Decreased by -31.94%
EPS This Year
-1.86
from -2.18
EPS Next Year
-1.71
from -1.86
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 52.5M | 55.1M | 57.9M | 60.8M | 88.6M |
| Avg | 13.1M | 8.9M | 11.2M | 33.3M | 42.3M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 320.4% | 548.2% | 440.9% | 166.2% |
| Avg | - | -31.9% | 25.9% | 196.1% | 27.1% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.73 | -1.35 | -1.56 | -1.72 | -1.56 |
| Avg | -1.86 | -1.71 | -1.77 | -2.04 | -2.25 |
| Low | -2.14 | -1.97 | -2.02 | -2.31 | -2.87 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.